Biocon India’s chairman bullish on Malaysia’s biotech prospects
- Country has almost all of the pieces in area to be a a hit hub
- Expects to see more biotech agencies discover right here over next five years
BIOCON Ltd founder and chairman Kiran Mazumdar-Shah (%, right), has an impressive presence approximately her. The deep and commanding voice provides to this. And she is simply ensuring that Malaysia's biotechnology objectives command global interest with her RM500-million (US$164-million) trendy bio pharma manufacturing facility.
Phase 1 can be completed via 2014 and could value RM250 million.
Aside from production, the 40-acre facility may even conduct research. Biocon is appeared as India’s foremost biotechnology business enterprise and turned into set up with the aid of Kiran in 1978.
The stakes are high because the skeptics are many. As a end result, she is disturbing wonderful execution.
“We ought to exhibit to the sector what Malaysia is capable of and what Indian investment can do,” she says.
The facility she is building in Iskandar Malaysia's Bio-XCell Park can be the biggest incorporated insulin manufacturing plant in Asia, and she wants to show the sector what India and Malaysia can do collectively.
“There is a lot of credibility at stake due to the fact there are loads of skeptics who preserve telling me that maybe I have made a mistake. But I tell them that I were ambitious sufficient to take this selection, and that perhaps they'll follow me. In fact, I am positive others will observe me,” she asserts.
If she sounds like a pal of Malaysia, she is. Kiran gave the keynote lecture at this May's BIO conference within the United States, and spoke approximately the state of biotech in Malaysia and why groups have to appearance critically into making an investment here. She is even seeking to persuade a former head of R&D at Biocon, who has began a seaweed-based renewable strength task, to seriously remember putting in place his evidence of idea plant in Malaysia.
“I told him Malaysia is helping in a huge way and has performed an remarkable process in phrases of permitting regulations. Many agencies will start trying to Malaysia and do now not be surprised if in the next 5 years you witness a larger presence of biotech agencies here,” she says.
And to suppose that she started out skeptical about Malaysia's grand aims of being a biotech player. As a part of the biotech International Advisory Panel, she gave coverage makers an entire set of guidelines and motion plans they had to put in force.
Her foundation was to take a look at what Singapore become doing and tough the Malaysian authorities to do more. “I did now not think they could do it however to my quality marvel, they got here lower back to me having accomplished the whole lot I recommended!”
Kiran then realized she had to positioned her money where her mouth become, and for this reason became the seed for her RM500-million facility planted, again in 2010.
Despite her bullishness but, she identifies the lack of high-quit expertise as being the most important lacking element that would derail Malaysia’s biotech push. “All the alternative ingredients of fulfillment are there, however you need enough portions of engineering, medical and technical skills to understand your biotech aims.”
It isn't so simple to blame academia for the lack of skills in the biotech-related industries. Kiran notes that without the pull from enterprise, humans gained’t come into those sectors, so possibilities need to be created first.
“It is a Catch-22,” she recognizes, however points to her upcoming facility as a catalyst to kick-begin and give momentum to the push to attract greater expertise into biotech-related fields.
Biocon is likewise gambling its element in developing this expertise pipeline. In September, Biocon Sdn Bhd, an entirely owned subsidiary of Biocon Ltd India, entered into a Memorandum of Understanding with Manipal Education Malaysia (MEM) to collaborate to broaden human capital for the biotechnology enterprise.
The MoU outlines the creation of an internship software and graduate employment software for the admission of Manipal International University (MIU) students and graduates to Biocon's Malaysia facility for education and employment.
It should be cited that the dealing with director of MEM is Datuk Iskandar Mizal Mahmood (percent above, left), the former CEO of BiotechCorp Malaysia.
Kiran acknowledges the vital function Iskandar performed in getting her to invest in Malaysia. At the MoU signing, Kiran joked that Iskandar needed to get into the training quarter due to the fact he guaranteed her that each one of Biocon’s wishes in Malaysia would be met. Biocon will want over 1,000 highly skilled capabilities at its Iskandar facility.
MEM’s flagship assignment is the Manipal International University. Its interim campus is in Kelana Jaya within the kingdom of Selangor, while its a hundred and forty-acre campus, costing over RM650 million (US$214 million), is being evolved in Nilai within the country of Negeri Sembilan. The Nilai campus could be operational by means of January, 2013.
Related Story:
Bio-XCell taking shape in Iskandar